Home » Stocks » LCTX

Lineage Cell Therapeutics, Inc. (LCTX)

Stock Price: $2.67 USD -0.09 (-3.26%)
Updated Jan 22, 2021 2:34 PM EST - Market open
Market Cap 413.98M
Revenue (ttm) 2.71M
Net Income (ttm) -27.16M
Shares Out 149.97M
EPS (ttm) -0.37
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 22
Last Price $2.67
Previous Close $2.76
Change ($) -0.09
Change (%) -3.26%
Day's Open 2.84
Day's Range 2.61 - 2.85
Day's Volume 1,339,895
52-Week Range 0.60 - 3.00

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
Business Wire - 1 day ago

CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #AMD--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies to...

Business Wire - 1 day ago

CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #AMD--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies fo...

Business Wire - 3 weeks ago

CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #AMD--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies fo...

Zacks Investment Research - 1 month ago

Investors need to pay close attention to Lineage Cell Therapeutics (LCTX) stock based on the movements in the options market lately.

Business Wire - 1 month ago

CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #AMD--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing three novel cell therapies f...

Business Wire - 1 month ago

CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #AMD--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies fo...

Seeking Alpha - 2 months ago

Lineage Cell Therapeutics, Inc. is a clinical-stage biotech company focused on developing therapeutics for degenerative retinal diseases, demyelination-related neurological conditions, and can...

Business Wire - 2 months ago

CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #DryAMD--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing three novel cell therapie...

Business Wire - 2 months ago

CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #AMD--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel cell therapies for unm...

Business Wire - 2 months ago

CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #AMD--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing three novel cell therapies f...

Seeking Alpha - 2 months ago

Lineage Cell Therapeutics, Inc. (LCTX) CEO Brian Culley on Q3 2020 Results - Earnings Call Transcript

Zacks Investment Research - 2 months ago

Lineage Cell (LCTX) delivered earnings and revenue surprises of 20.00% and -12.15%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

Business Wire - 2 months ago

CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #AMD--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel cell therapies for unm...

Business Wire - 2 months ago

CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #AMD--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel cell therapies for unm...

Business Wire - 2 months ago

CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #AMD--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel cell therapies for unm...

Business Wire - 3 months ago

CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #AMD--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel cell therapies for unm...

Business Wire - 3 months ago

CARLSBAD, Calif. & LONDON--(BUSINESS WIRE)---- $LCTX #AMD--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel cell therapie...

Business Wire - 4 months ago

CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #AMD--Lineage Cell Therapeutics, Inc.

Business Wire - 4 months ago

CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #AMD--Lineage Cell Therapeutics, Inc.

Business Wire - 4 months ago

CARLSBAD, Calif. & ALAMEDA, Calif.

Business Wire - 4 months ago

ALAMEDA, Calif. & CARLSBAD, Calif.

Other stocks mentioned: AGE
Business Wire - 4 months ago

CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #AMD--Lineage Cell Therapeutics, Inc.

Business Wire - 4 months ago

CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #AMD--Lineage Cell Therapeutics, Inc.

Business Wire - 4 months ago

CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #AMD--Lineage Cell Therapeutics, Inc.

Seeking Alpha - 5 months ago

Lineage Cell Therapeutics, Inc. (LCTX) CEO Brian Culley on Q2 2020 Results - Earnings Call Transcript

Business Wire - 5 months ago

CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #AMD--Lineage Cell Therapeutics, Inc.

Business Wire - 5 months ago

CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #AMD--Lineage Cell Therapeutics, Inc.

Seeking Alpha - 6 months ago

Lineage Cell Therapeutics Is A High-Risk But High-Reward Opportunity To Consider

Seeking Alpha - 8 months ago

Lineage Cell Therapeutics, Inc. (LCTX) CEO Brian Culley on Q1 2020 Results - Earnings Call Transcript

Zacks Investment Research - 8 months ago

Is (LCTX) Outperforming Other Medical Stocks This Year?

Zacks Investment Research - 8 months ago

On Lineage Cell's (LCTX) Q1 earnings call, investor focus will be on its progress with the pipeline candidate OpRegen, currently being developed for treating dry AMD, as well as other pipeline...

Zacks Investment Research - 8 months ago

As of late, it has definitely been a great time to be an investor Lineage Cell Therapeutics

Zacks Investment Research - 8 months ago

Lineage Cell (LCTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Investment Research - 9 months ago

Lineage Cell Therapeutics, Inc. (LCTX) has been struggling lately, but the selling pressure may be coming to an end soon.

Seeking Alpha - 10 months ago

Lineage Cell Therapeutics, Inc. (LCTX) CEO Brian Culley on Q4 2019 Results - Earnings Call Transcript

Zacks Investment Research - 10 months ago

Lineage Cell (LCTX) delivered earnings and revenue surprises of 57.14% and 108.57%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

Zacks Investment Research - 10 months ago

Lineage Cell (LCTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Investment Research - 1 year ago

BioTime, Inc. (LCTX) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects.

Seeking Alpha - 1 year ago

Lineage Cell Therapeutics, Inc. (LCTX) CEO Brian Culley on Q3 2019 Results - Earnings Call Transcript

Seeking Alpha - 1 year ago

Lineage Cell Therapeutics has suffered a marked decreasing trend in recent years.

About LCTX

Lineage Cell Therapeutics, a clinical-stage biotechnology company, focuses on developing and commercializing therapies for the treatment of degenerative diseases in the United States and internationally. The company's lead product candidates include OpRegen, a retinal pigment epithelium cell replacement therapy, which is in Phase I/IIa clinical trial for the treatment of the dry age-related macular degeneration; OPC1, an oligodendrocyte progenitor cell therapy that is in Phase I/IIa multicenter clinical trial for the treatment of acute spinal c... [Read more...]

Industry
Biotechnology
Founded
1990
CEO
Brian Culley
Employees
50
Stock Exchange
NYSEAMERICAN
Ticker Symbol
LCTX
Full Company Profile

Financial Performance

In 2019, LCTX's revenue was $3.52 million, a decrease of -29.53% compared to the previous year's $4.99 million. Losses were -$11.71 million, -74.54% less than in 2018.

Financial Statements

Analyst Forecasts

According to 5 analysts, the average rating for LCTX stock is "Buy." The 12-month stock price forecast is 4.80, which is an increase of 79.78% from the latest price.

Price Target
$4.80
(79.78% upside)
Analyst Consensus: Buy